Genmab A/S

Genmab A/S Working Capital Turnover

The Working Capital Turnover of Genmab A/S (GMAB.CO) as of Nov 10, 2026 is 0.80. In the previous year, Working Capital Turnover was 0.94 — a change of -14.99% (lower).

Working Capital Turnover

0.80

YoY

-14.99%

Last updated:

Working Capital Turnover of Genmab A/S is 2025 0.80 . Working Capital Turnover of Genmab A/S was 2024 0.94 . It decreases by -14.99% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Working Capital Turnover of Genmab A/S is 0.80 in 2025.

Working Capital Turnover of Genmab A/S changed from 0.94 to 0.80, representing a -14.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Turnover Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Working capital turnover measures how efficiently a company uses its working capital to generate revenue. Higher ratios indicate more efficient short-term asset utilization.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Working Capital Turnover's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Working Capital Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Working Capital Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Genmab A/S

All Key Metrics — Genmab A/S